London: Friday, December 29, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 29, 2017, the issued share capital of Chi-Med consisted of 66,447,037 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.
The above figure of 66,447,037 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority’s Disclosure Rules and Transparency Rules.
For illustrative purposes only, the 66,447,037 ordinary shares would be equivalent to 66,447,037 CREST depositary interests (each equating to one ordinary share) which are traded on AIM or, if the CREST depositary interests were converted in their entirety, equivalent to 132,894,074 American depositary shares (each equating to one-half of one ordinary share) which are traded on Nasdaq.
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.
Chi‑Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi‑med.com.
Mark Lee, Senior Vice President, Corporate Finance & Development
+852 2121 8200
Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Brad Miles, BMC Communications
+1 (917) 570 7340 (Mobile)
bmiles@bmccommunications.com
Susan Duffy, BMC Communications
+1 (917) 499 8887 (Mobile)
sduffy@bmccommunications.com
Matt Beck, The Trout Group
+1 (917) 415 1750 (Mobile)
mbeck@troutgroup.com
David Dible, Citigate Dewe Rogerson
+44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Richard Gray / Andrew Potts
+44 (20) 7886 2500
London: Friday, December 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:
| 1. | Name of applicant: | Hutchison China MediTech Limited |
| 2. | Name of scheme: | Hutchison China MediTech Limited Share Option Schemes |
| 3. | Period of return: | From June 29, 2017 to December 28, 2017 |
| 4. | Balance under scheme from previous return: | 1,329,927 ordinary shares of US$1 each |
| 5. | The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return: | Nil |
| 6. | Number of securities issued/allotted under scheme during period: | 24,928 ordinary shares of US$1 each |
| 7. | Balance under scheme not yet issued/allotted at end of the period: | 1,304,999 ordinary shares of US$1 each |
| 8. | Number and class of securities originally listed and the date of admission: | 2,560,606 ordinary shares of US$1 each admitted on June 26, 2007 |
| 9. | Total number of securities in issue at the end of the period: | 66,447,037 ordinary shares of US$1 each |
| Name of contact: | Christian Hogg | |
| Address of contact: | 21/F., Hutchison House, 10 Harcourt Road, Hong Kong | |
| Telephone number of contact: | +852 2121 8200 |
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.
Chi‑Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi‑med.com.
Mark Lee, Senior Vice President, Corporate Finance & Development
+852 2121 8200
Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Brad Miles, BMC Communications
+1 (917) 570 7340 (Mobile)
bmiles@bmccommunications.com
Susan Duffy, BMC Communications
+1 (917) 499 8887 (Mobile)
sduffy@bmccommunications.com
Matt Beck, The Trout Group
+1 (917) 415 1750 (Mobile)
mbeck@troutgroup.com
David Dible, Citigate Dewe Rogerson
+44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Richard Gray / Andrew Potts
+44 (20) 7886 2500
2017年12 月15日：和黃醫藥今日宣佈在美國啟動呋喹替尼I期橋接臨床試驗。呋喹替尼是一種高選擇性強效口服血管內皮生長因子受體（VEGFR）1,2及3的抑製劑。呋喹替尼在中國以結直腸癌、肺癌或胃癌為適應症的多項II期和III期臨床研究均達到了主要終點。此次啟動的是一項多中心開放標籤的I期臨床試驗，旨在評估呋喹替尼在美國晚期實體瘤患者中的安全性、耐受性和藥代動力學特性。首位受試者已於12月初接受給藥治療。該研究詳情可登錄clinicaltrials.gov，檢索NCT03251378查看。
結直腸癌：2017年6月，中國食品藥品監督管理總局（CFDA）受理呋喹替尼以晚期結直腸癌（CRC）為適應症的新藥上市申請；2017年9月，CFDA公佈因呋喹替尼具有明顯臨床價值而授予其優先審評的資格。呋喹替尼的新藥上市申請基於一項在中國成功完成的III期關鍵性註冊研究FRESCO。該研究共計納入416名CRC患者，其結果於2017年6月5日在美國臨床腫瘤學會年會上以口頭報告的形式公佈（clinicaltrials.gov註冊號NCT02314819）。呋喹替尼的3 項早期臨床研究為FRESCO研究的開展奠定了基礎，這3 項早期臨床研究包括：納入40名實體瘤患者的I期臨床研究、納入62名結直腸癌患者的Ib 期臨床研究以及納入71名結直腸癌患者的II期臨床研究。
肺癌：呋喹替尼以三線治療非小細胞肺癌（NSCLC）為適應症的III期關鍵性臨床試驗FALUCA（clinicaltrials.gov註冊號NCT02691299）目前也正在中國展開，預計將納入約520名患者。該研究基於一項納入91名三線NSCLC患者的II期臨床試驗。另有一項II期臨床試驗也正在進行中，該試驗以呋喹替尼聯合易瑞沙® （吉非替尼）作為一線療法，治療晚期或轉移性NSCLC（clinicaltrials .gov註冊號NCT02976116）。
胃癌：呋喹替尼聯合泰素® （紫杉醇）以晚期胃癌或胃食管結合部（GEJ）腺癌為適應症的III期關鍵性臨床試驗FRUTIGA（clinicaltrials.gov註冊號NCT03223376）已於2017年10月啟動，預計將納入超過500名患者。
在中國范圍內，呋喹替尼由和黃醫藥和禮來合作開發。
呋喹替尼（HMPL-013）是一種新型的高選擇性小分子候選藥物。臨床研究證實：通過一日一次的口服劑量即可有效的抑制血管內皮生長因子受體（VEGFR），且脫靶毒性低於其他靶向療法。呋喹替尼良好的耐受性以及無藥物間相互作用的特性，為其與其他癌症療法相聯合提供了理論支持，例如當前正在進行的呋喹替尼聯合化療或其他靶向治療的臨床研究。
癌症進入到晚期，腫瘤會分泌大量VEGFR的配體蛋白-血管內皮生長因子(VEGF)，以促進腫瘤組織周圍形成大量的血管（血管生成），為腫瘤細胞的生長提供更多的血流、氧氣和營養。VEGF和其受體VEGFR在腫瘤的血管生成中起到了至關重要的作用，而呋喹替尼可以抑制VEGF/VEGFR通路。對VEGF/VEGFR相關通路的抑制可以阻斷腫瘤新生血管形成，從而成為防止腫瘤增長和入侵的一種重要的治療策略。
Four Seasons Hotel, Hong Kong